LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_015338.5:c.3184C>T
ASXL1
· NP_056153.2:p.(Pro1062Ser)
· NM_015338.5
GRCh37: chr20:31023699 C>T
·
GRCh38: chr20:32435896 C>T
Gene:
ASXL1
Transcript:
NM_015338.5
Final call
VUS
PM2 moderate
BP4 supporting
Variant details
Gene
ASXL1
Transcript
NM_015338.5
Protein
NP_056153.2:p.(Pro1062Ser)
gnomAD AF
1.610734928786931e-05 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
VUS: PM2 (moderate) is met because gnomAD v4.1 shows an allele frequency of 1.61073e-05 with zero homozygotes.
2
VUS: BP4 (supporting) is met because the missense REVEL score is 0.018, below the 0.29 threshold.
Final determination:
Under generic ACMG/AMP 2015 rules, one moderate pathogenic criterion and one supporting benign criterion do not independently satisfy any pathogenic, likely pathogenic, benign, or likely benign combination, so the call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PS1 | Not met | Not met: p.Pro1062Ser has no documented previously established pathogenic same-amino-acid change in the available evidence. |
clinvar
|
| PS2 | Not assessed | Not assessed: no affected-proband, confirmed maternity and paternity, or family-history evidence is documented for this variant. |
|
| PS3 | Not assessed | Not assessed: no validated in vitro or in vivo assay of p.Pro1062Ser with documented controls or biological functional readout is available. |
|
| PS4 | Not assessed | Not assessed: no affected/control counts or variant-specific disease case observation were available to evaluate increased prevalence or calculate an odds ratio. |
gnomad_v4
|
| PM1 | Not met | Not met: Cancer Hotspots found no statistically significant hotspot for ASXL1 P1062, and no qualifying critical-domain evidence is available. |
hotspots
cosmic
|
| PM2 | Met | Met at Moderate: gnomAD v4.1 AF is 1.61073e-05, below the 0.0001 generic PM2 cutoff, with 0 homozygotes. |
gnomad_v2
gnomad_v4
|
| PM3 | N/A | Not applicable: PM3 requires a recessive disorder, whereas the available ASXL1 germline disease context is dominant and no recessive inheritance is documented. |
|
| PM4 | N/A | Not applicable: PM4 requires a protein-length change, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PM5 | Not met | Not met: the PM5 search contains zero same-residue candidates, and no different pathogenic missense change at Pro1062 is documented. |
pm5_candidates
clinvar
|
| PM6 | Not assessed | Not assessed: no assumed-de novo observation in an affected patient or parental-testing information is documented. |
|
| PP1 | Not assessed | Not assessed: no affected-relative genotypes, phenotype data, pedigree, or informative meioses are documented for co-segregation. |
|
| PP2 | Not assessed | Not assessed: the available evidence does not establish both low benign missense variation and a common disease-causing missense mechanism for ASXL1. |
oncokb
|
| PP3 | Not met | Not met: missense REVEL score 0.018 is below the PP3 supporting threshold of >= 0.644. |
revel
|
| PP4 | Not assessed | Not assessed: no patient phenotype, family history, or specific disease diagnosis was supplied to judge highly specific phenotype evidence. |
|
| PP5 | Not met | Not met: ClinVar reports Uncertain significance from one non-expert submitter, not an exact-variant expert-panel Pathogenic or Likely pathogenic classification. |
clinvar
|
| BA1 | Not met | Not met: grpmax FAF is 1.533e-05 in gnomAD v4.1, far below the 0.05 BA1 threshold. |
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: the highest applicable grpmax FAF is 1.533e-05, far below the 0.01 generic BS1 threshold. |
gnomad_v2
gnomad_v4
|
| BS2 | Not met | Not met: gnomAD reports 0 homozygotes, with no documented healthy adult individual carrying the disease-relevant genotype. |
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no validated in vitro or in vivo assay demonstrates preserved p.Pro1062Ser function or normal splicing with documented controls. |
|
| BS4 | Not assessed | Not assessed: no affected-family-member genotypes or phenotype-confirmed non-segregation observations are documented. |
|
| BP1 | Not assessed | Not assessed: loss-of-function biology is supported, but a citable source showing that ASXL1 disease variants are primarily truncating is absent. |
|
| BP2 | Not assessed | Not assessed: no pathogenic partner variant or parental/offspring phase result establishes the required cis or trans configuration for BP2. |
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| BP4 | Met | Met at supporting: missense REVEL score 0.018 meets the BP4 threshold of <= 0.29. |
revel
|
| BP5 | Not met | Not met: COSMIC records two somatic cancer occurrences but provides no disease case with an independently established alternate molecular basis. |
cosmic
|
| BP6 | Not met | Not met: ClinVar reports Uncertain significance from one non-expert submitter, not an exact-variant expert-panel Benign or Likely benign classification. |
clinvar
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous variant, and this is a missense variant. |
generic_acmg_combination_rules
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.